U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H21NO3
Molecular Weight 311.3749
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NALORPHINE

SMILES

[H][C@@]12OC3=C4C(C[C@H]5N(CC=C)CC[C@@]14[C@@]5([H])C=C[C@@H]2O)=CC=C3O

InChI

InChIKey=UIQMVEYFGZJHCZ-SSTWWWIQSA-N
InChI=1S/C19H21NO3/c1-2-8-20-9-7-19-12-4-6-15(22)18(19)23-17-14(21)5-3-11(16(17)19)10-13(12)20/h2-6,12-13,15,18,21-22H,1,7-10H2/t12-,13+,15-,18-,19-/m0/s1

HIDE SMILES / InChI

Molecular Formula C19H21NO3
Molecular Weight 311.3749
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Nalorphine has a mixed opioid agonist-antagonist properties. Nalorphine inhibits the cholinesterases of mouse brain, bovine erythrocytes and horse serum. It acts on mu-, k- and sigma-opioid receptors. Nalorfin by virtue of the agonistic effect has an analgesic effect but to a much lesser extent than morphine. Initially, before the appearance of a "pure" morphine-naloxone antagonist, nalorphine was used as an antidote for severe respiratory depression and other body function disorders caused by acute poisoning in case of an overdose of morphine, promedol, fentanyl or other narcotic analgesics, or with increased sensitivity to them. At present, nalorphine is practically not used for this purpose. It was replaced by naloxone. Large doses of nalorphine can cause nausea, cramps, drowsiness, headache, mental stimulation.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
1.6 nM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
Norfin

Cmax

ValueDoseCo-administeredAnalytePopulation
1.12 μg/g
2 mg/kg single, subcutaneous
NALORPHINE brain
Canis lupus

AUC

ValueDoseCo-administeredAnalytePopulation
1.17 μg × h/g
2 mg/kg single, subcutaneous
NALORPHINE brain
Canis lupus

T1/2

ValueDoseCo-administeredAnalytePopulation
23 min
2 mg/kg single, subcutaneous
NALORPHINE brain
Canis lupus

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer





Drug as victim

PubMed

Sample Use Guides

In Vivo Use Guide
Adults appoint 0,005 - 0,01 g (1 - 2 ml of a 0.5% solution). If the effect is insufficient, the injections are repeated at intervals of 10 to 15 minutes. The total dose should not exceed 0.04 g (8 ml of 0.5% solution).
Route of Administration: Other
In Vitro Use Guide
Maximum stimulation of [35S]GTPyS binding by Nalorphine using a single saturating concentration of ligand (10 uM) was compared with stimulation by DAAMGO (10 uM). Intrinsic activity determined for Nalorphine in C6 glioma cells was 9%.
Substance Class Chemical
Record UNII
U59WB2WRY2
Record Status Validated (UNII)
Record Version